Primary Hyperlipidemia: Fresh look at an LDL-C Therapy and its Long-Term Data

Be part of the knowledge.

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Primary Hyperlipidemia: Fresh look at an LDL-C Therapy and its Long-Term Data



ReachMD Healthcare Image

What is the long-term efficacy and safety data of an LDL-C therapy for patients with primary hyperlipidemia? Find out here.

  • Sponsored by

  • Overview

    The long-term efficacy and safety of LEQVIO® (inclisiran)  was studied in ORION-8, which is a Phase 3 long-term extension trial. This trial included patients with ASCVD, increased risk for CVD, or HeFH with elevated LDL-C despite ongoing treatment with statin therapy with or without ezetimibe. To learn more about the efficacy and safety of LEQVIO and to hear the trial results, join Dr Rigved Tadwalkar, Partner and Consultative Cardiologist with Pacific Heart Institute from Santa Monica, California, and Dr Briana Costello, Cardiologist from The Texas Heart Institute Center for Cardiovascular Care in Houston, Texas.

    Dr Tadwalkar and Dr Costello have been compensated for their time.


    LEQVIO (inclisiran) injection is indicated as an adjunct to diet and statin therapy for the treatment of adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH), to reduce low-density lipoprotein cholesterol (LDL-C).


    Adverse reactions in clinical trials (≥3% of patients treated with LEQVIO and more frequently than placebo) were injection site reaction, arthralgia, and bronchitis.

    Please click here for LEQVIO full Prescribing Information.

    1/24     315463

Schedule28 Feb 2024